Neurocrine Biosciences Management
Management criteria checks 3/4
Neurocrine Biosciences' CEO is Kevin Gorman, appointed in Jan 2008, has a tenure of 16.25 years. total yearly compensation is $15.75M, comprised of 6% salary and 94% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $70.89M. The average tenure of the management team and the board of directors is 6.4 years and 11.3 years respectively.
Key information
Kevin Gorman
Chief executive officer
US$15.8m
Total compensation
| CEO salary percentage | 6.0% |
| CEO tenure | 16.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 6.4yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts
Sep 26Neurocrine to acquire U.K.-based biotech Diurnal
Aug 30Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial
Aug 05Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly
Jul 26Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares
Jul 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$16m | US$946k | US$250m |
| Sep 30 2023 | n/a | n/a | US$191m |
| Jun 30 2023 | n/a | n/a | US$176m |
| Mar 31 2023 | n/a | n/a | US$64m |
| Dec 31 2022 | US$12m | US$860k | US$155m |
| Sep 30 2022 | n/a | n/a | US$58m |
| Jun 30 2022 | n/a | n/a | US$12m |
| Mar 31 2022 | n/a | n/a | US$71m |
| Dec 31 2021 | US$14m | US$825k | US$90m |
| Sep 30 2021 | n/a | n/a | US$445m |
| Jun 30 2021 | n/a | n/a | US$365m |
| Mar 31 2021 | n/a | n/a | US$402m |
| Dec 31 2020 | US$14m | US$775k | US$407m |
| Sep 30 2020 | n/a | n/a | US$93m |
| Jun 30 2020 | n/a | n/a | US$205m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$9m | US$725k | US$37m |
| Sep 30 2019 | n/a | n/a | US$21m |
| Jun 30 2019 | n/a | n/a | US$18m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | US$9m | US$675k | US$21m |
| Sep 30 2018 | n/a | n/a | US$10m |
| Jun 30 2018 | n/a | n/a | -US$52m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$8m | US$640k | -US$143m |
Compensation vs Market: Kevin's total compensation ($USD15.75M) is about average for companies of similar size in the US market ($USD13.53M).
Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.
CEO
Kevin Gorman (65 yo)
16.3yrs
Tenure
US$15,750,812
Compensation
Dr. Kevin C. Gorman, Ph D., has been Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008 and served as its President since January 2008. Dr. Gorman is a Founder of Neurocrine Bioscie...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 16.3yrs | US$15.75m | 0.51% $ 70.9m | |
| Chief Financial Officer | 6.4yrs | US$6.06m | 0.031% $ 4.3m | |
| Chief Scientific Officer | 2.4yrs | US$7.22m | 0.013% $ 1.8m | |
| Chief Business Development & Strategy Officer | 13.3yrs | US$5.99m | 0.13% $ 18.7m | |
| Chief Medical Officer | 6.3yrs | US$5.87m | 0.024% $ 3.3m | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 9.5yrs | US$4.72m | 0.040% $ 5.5m | |
| Chief Human Resources Officer | 6.6yrs | no data | 0.018% $ 2.5m | |
| Chief Commercial Officer | 8.9yrs | US$5.81m | 0.041% $ 5.6m | |
| Chief Corporate Affairs Officer | 4.6yrs | no data | 0.0049% $ 674.8k | |
| Chief Regulatory Officer | 1.5yrs | no data | 0.0075% $ 1.0m | |
| Exclusive Consultant | 6.3yrs | US$3.10m | no data |
6.4yrs
Average Tenure
57yo
Average Age
Experienced Management: NBIX's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 16.3yrs | US$15.75m | 0.51% $ 70.9m | |
| Independent Director | less than a year | US$813.45k | 0% $ 0 | |
| Independent Director | 26yrs | US$492.04k | 0.029% $ 4.1m | |
| Independent Director | 25yrs | US$479.54k | 0.022% $ 3.1m | |
| Independent Chairman of the Board | 14.2yrs | US$495.04k | 0.051% $ 7.1m | |
| Independent Director | 31.2yrs | US$460.11k | 0.12% $ 16.1m | |
| Independent Director | 8.5yrs | US$479.54k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$497.11k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$475.11k | 0% $ 0 | |
| Independent Director | 3yrs | US$467.61k | 0% $ 0 |
11.3yrs
Average Tenure
68yo
Average Age
Experienced Board: NBIX's board of directors are seasoned and experienced ( 11.3 years average tenure).